Annual CFF
N/A
December 31, 2023
Summary
- PTIX annual cash flow from financing activities is not available.
Performance
PTIX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
$317.00 K
+$272.50 K+612.36%
September 30, 2024
Summary
- As of February 24, 2025, PTIX quarterly cash flow from financing activities is $317.00 thousand, with the most recent change of +$272.50 thousand (+612.36%) on September 30, 2024.
- Over the past year, PTIX quarterly CFF has stayed the same.
- PTIX quarterly CFF is now -98.20% below its all-time high of $17.64 million, reached on March 31, 2007.
Performance
PTIX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$361.50 K
+$317.00 K+712.36%
September 30, 2024
Summary
- As of February 24, 2025, PTIX TTM cash flow from financing activities is $361.50 thousand, with the most recent change of +$317.00 thousand (+712.36%) on September 30, 2024.
- Over the past year, PTIX TTM CFF has stayed the same.
- PTIX TTM CFF is now -98.00% below its all-time high of $18.10 million, reached on March 31, 2007.
Performance
PTIX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PTIX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | 0.0% | 0.0% |
| 3 y3 years | - | 0.0% | 0.0% |
| 5 y5 years | - | 0.0% | 0.0% |
PTIX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | -100.0% | -97.1% | -100.0% | ||
| 5 y | 5-year | -97.5% | -100.0% | -97.2% | -100.0% | ||
| alltime | all time | -98.2% | +115.7% | -98.0% | +107.3% |
Protagenic Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $317.00 K(+612.4%) | $361.50 K(+712.4%) |
| Jun 2024 | - | $44.50 K(>+9900.0%) | $44.50 K(>+9900.0%) |
| Sep 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2023 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2021 | $12.58 M(+928.1%) | $0.00(0.0%) | $12.58 M(0.0%) |
| Sep 2021 | - | $0.00(-100.0%) | $12.58 M(-2.5%) |
| Jun 2021 | - | $12.45 M(+9695.8%) | $12.90 M(+1164.2%) |
| Mar 2021 | - | $127.10 K(>+9900.0%) | $1.02 M(-16.6%) |
| Dec 2020 | $1.22 M(+82.6%) | $0.00(-100.0%) | $1.22 M(-35.4%) |
| Sep 2020 | - | $323.40 K(-43.3%) | $1.89 M(+20.6%) |
| Jun 2020 | - | $570.00 K(+72.7%) | $1.57 M(+57.0%) |
| Mar 2020 | - | $330.00 K(-50.7%) | $1.00 M(+49.3%) |
| Dec 2019 | $670.00 K(>+9900.0%) | $670.00 K(>+9900.0%) | $670.00 K(>+9900.0%) |
| Sep 2019 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2019 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2019 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2018 | $0.00(-100.0%) | - | - |
| Dec 2016 | $4.28 M(+1160.0%) | -$18.50 K(<-9900.0%) | $4.28 M(-2.7%) |
| Sep 2016 | - | $0.00(-100.0%) | $4.40 M(-1.1%) |
| Jun 2016 | - | $505.20 K(-86.7%) | $4.45 M(+10.0%) |
| Mar 2016 | - | $3.80 M(+3697.3%) | $4.05 M(+1518.9%) |
| Dec 2015 | - | $100.00 K(+100.0%) | $250.00 K(-16.7%) |
| Sep 2015 | - | $50.00 K(-50.0%) | $300.00 K(-11.8%) |
| Jun 2015 | $340.00 K(+94.3%) | $100.00 K(>+9900.0%) | $340.00 K(+41.7%) |
| Mar 2015 | - | $0.00(-100.0%) | $240.00 K(-42.2%) |
| Dec 2014 | - | $150.00 K(+66.7%) | $415.00 K(+56.6%) |
| Sep 2014 | - | $90.00 K(>+9900.0%) | $265.00 K(+51.4%) |
| Jun 2014 | $175.00 K(+464.5%) | $0.00(-100.0%) | $175.00 K(0.0%) |
| Mar 2014 | - | $175.00 K(>+9900.0%) | $175.00 K(>+9900.0%) |
| Dec 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2013 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Jun 2013 | $31.00 K(-444.4%) | - | - |
| Sep 2011 | - | -$2000.00(-100.0%) | $4.36 M(-0.0%) |
| Jun 2011 | - | $4.30 M(+7587.5%) | $4.36 M(+9178.7%) |
| Mar 2011 | - | $56.00 K(>+9900.0%) | $47.00 K(-622.2%) |
| Dec 2010 | -$9000.00(-99.7%) | $0.00(0.0%) | -$9000.00(0.0%) |
| Sep 2010 | - | $0.00(-100.0%) | -$9000.00(-107.0%) |
| Jun 2010 | - | -$9000.00(<-9900.0%) | $129.00 K(-106.9%) |
| Mar 2010 | - | $0.00(0.0%) | -$1.88 M(-33.8%) |
| Dec 2009 | -$2.84 M | $0.00(-100.0%) | -$2.84 M(-13.8%) |
| Sep 2009 | - | $138.00 K(-106.8%) | -$3.29 M(-33.2%) |
| Jun 2009 | - | -$2.02 M(+110.4%) | -$4.93 M(+35.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2009 | - | -$959.00 K(+110.8%) | -$3.63 M(+29.4%) |
| Dec 2008 | -$2.80 M(-116.1%) | -$455.00 K(-69.6%) | -$2.80 M(+18.8%) |
| Sep 2008 | - | -$1.50 M(+109.2%) | -$2.36 M(+163.7%) |
| Jun 2008 | - | -$716.00 K(+430.4%) | -$895.00 K(+190.6%) |
| Mar 2008 | - | -$135.00 K(+1127.3%) | -$308.00 K(-101.8%) |
| Dec 2007 | $17.46 M(-3351.8%) | -$11.00 K(-66.7%) | $17.46 M(-0.1%) |
| Sep 2007 | - | -$33.00 K(-74.4%) | $17.47 M(-0.3%) |
| Jun 2007 | - | -$129.00 K(-100.7%) | $17.52 M(-3.2%) |
| Mar 2007 | - | $17.64 M(>+9900.0%) | $18.10 M(>+9900.0%) |
| Dec 2006 | -$537.00 K(-551.3%) | - | - |
| Oct 2006 | - | $19.00 K(-95.7%) | $87.30 K(-26.6%) |
| Jul 2006 | - | $443.00 K(-205.9%) | $119.00 K(-136.7%) |
| Jul 2006 | $119.00 K(+170.5%) | - | - |
| Apr 2006 | - | -$418.20 K(-1061.4%) | -$324.00 K(-443.9%) |
| Jan 2006 | - | $43.50 K(-14.2%) | $94.20 K(+85.8%) |
| Oct 2005 | - | $50.70 K(-95.0%) | $50.70 K(-74.3%) |
| Jul 2005 | $44.00 K(>+9900.0%) | - | - |
| Jul 2004 | $0.00(-100.0%) | - | - |
| Apr 2003 | - | $1.02 M(-196.3%) | $197.00 K(-113.1%) |
| Jan 2003 | - | -$1.06 M(-218.3%) | -$1.51 M(+313.2%) |
| Oct 2002 | - | $897.00 K(-235.7%) | -$365.00 K(-35.7%) |
| Jul 2002 | -$568.00 K(-222.9%) | -$661.00 K(-3.2%) | -$568.00 K(-49.4%) |
| Apr 2002 | - | -$683.00 K(-932.9%) | -$1.12 M(-493.7%) |
| Jan 2002 | - | $82.00 K(-88.2%) | $285.00 K(-68.2%) |
| Oct 2001 | - | $694.00 K(-157.1%) | $896.00 K(+93.9%) |
| Jul 2001 | $462.00 K(-123.4%) | -$1.22 M(-267.8%) | $462.00 K(-17.8%) |
| Apr 2001 | - | $724.00 K(+4.5%) | $562.00 K(-168.1%) |
| Jan 2001 | - | $693.00 K(+166.5%) | -$825.00 K(-57.0%) |
| Oct 2000 | - | $260.00 K(-123.3%) | -$1.92 M(-3.0%) |
| Jul 2000 | -$1.98 M(-225.0%) | -$1.11 M(+68.2%) | -$1.98 M(+83.1%) |
| Apr 2000 | - | -$663.00 K(+65.8%) | -$1.08 M(-323.6%) |
| Jan 2000 | - | -$400.00 K(-300.0%) | $483.00 K(-50.9%) |
| Oct 1999 | - | $200.00 K(-192.2%) | $983.00 K(-37.9%) |
| Jul 1999 | $1.58 M(-59.1%) | -$217.00 K(-124.1%) | $1.58 M(+24.2%) |
| Apr 1999 | - | $900.00 K(+800.0%) | $1.27 M(-7.3%) |
| Jan 1999 | - | $100.00 K(-87.5%) | $1.38 M(-68.6%) |
| Oct 1998 | - | $800.00 K(-252.4%) | $4.38 M(+12.9%) |
| Jul 1998 | $3.88 M(-0.6%) | -$525.00 K(-152.5%) | $3.88 M(-11.9%) |
| Apr 1998 | - | $1.00 M(-67.7%) | $4.40 M(+29.4%) |
| Jan 1998 | - | $3.10 M(+933.3%) | $3.40 M(+1033.3%) |
| Oct 1997 | - | $300.00 K | $300.00 K |
| Jul 1997 | $3.90 M | - | - |
FAQ
- What is the all time high annual CFF for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly CFF year-on-year change?
- What is Protagenic Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Protagenic Therapeutics?
- What is Protagenic Therapeutics TTM CFF year-on-year change?
What is the all time high annual CFF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high annual cash flow from financing activities is $17.46 M
What is Protagenic Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of PTIX is $317.00 K
What is the all time high quarterly CFF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high quarterly cash flow from financing activities is $17.64 M
What is Protagenic Therapeutics quarterly CFF year-on-year change?
Over the past year, PTIX quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Protagenic Therapeutics TTM cash flow from financing activities?
The current TTM CFF of PTIX is $361.50 K
What is the all time high TTM CFF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high TTM cash flow from financing activities is $18.10 M
What is Protagenic Therapeutics TTM CFF year-on-year change?
Over the past year, PTIX TTM cash flow from financing activities has changed by $0.00 (0.00%)